Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

For Immediate Release Chicago, IL – December 9, 2025 – Today, Zacks Equity Research discusses Sandoz SDZNY, Teva ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Policy swings have made it a slippery year for pharma ...

Generic drugmakers continue to navigate a challenging U.S. market defined by persistent price erosion, intense competition and structurally thin margins. While demand for generics remains steady, ...

Teva Pharmaceutical Industries Limited’s TEVA stock has been trading above its 50-day and 200-day simple moving averages ...

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...

For the first time in decades, the US Food and Drug Administration has signed off on new antibiotics to fight gonorrhea. The approvals come at a critical moment: The sexually transmitted infection is ...

FDA approves Johnson & Johnson's Rybrevant Faspro for EGFR lung cancer and expands TRUFILL use for chronic subdural hematoma ...

Oral GnRH antagonists like Myfembree, Yselty, and Oriahnn now lead uterine fibroid treatment, offering high efficacy in ...

•WHO says despite the uplifting results, it is important to temper expectations because there are still some important safety and implementation issues to address. •The trial launched in 2017 enrolled ...